HitGen Extends and Expands Research Collaboration and License Agreement with MSD to Build and Screen Novel DNA-Encoded Libraries
Chengdu, China, July 30, 2018 HitGen Ltd. is pleased to announce that the company has extended and expanded its agreement with MSD, known as Merck & Co., Inc, Kenilworth NJ., USA into a multi-year research collaboration and license agreement to build and screen novel DNA-encoded libraries (DELs) in order to discover potential unique small molecule assets to be used in drug discovery and development. Through the collaboration, HitGen and MSD scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for MSD’s drug discovery efforts. In addition, HitGen will interrogate their own DELs, consisting of hundreds of billions of compounds, against a selected number of MSD’s therapeutic targets. Novel lead compounds from the HitGen DELs will be licensed exclusively to MSD for further research and development. MSD will support the research at HitGen.